Article
A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
Human mutation - 1 Jan 2012
Lindor Noralane M, Guidugli Lucia, Wang Xianshu, Vallée Maxime P, Monteiro Alvaro N A, Tavtigian Sean, Goldgar David E, Couch Fergus J
Abstract excerpt
Clinical mutation screening of the BRCA1 and BRCA2 genes for the presence of germline inactivating mutations is used to identify individuals at elevated risk of breast and ovarian cancer. Variants identified during screening are usually classified as pathogenic (increased risk of cancer) or not pathogenic (no increased risk of cancer). However, a significant proportion of genetic tests yields variants of...
Topics
- Adult
- Alleles
- Breast Neoplasms
- Codon
- Exons
- Female
- Genes, BRCA1
- Genes, BRCA2
- Genetic Predisposition to Disease
- Genetic Testing
- Genetic Variation
